Evidence map›Paper›PMID 20079712›Full record

ArticleBiochemical and biophysical research communications2010

Ankyrin recognizes both surface character and shape of the 14-15 di-repeat of beta-spectrin.

Penelope J La-Borde, Paul R Stabach, Ivana Simonović, Jon S Morrow, Miljan Simonović

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Do we already know how spectrin attracts ankyrin?Cellular and molecular life sciences : CMLS · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Penelope J La-BordeUniversity of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, 900 S. Ashland Ave., MBRB 1170, Chicago, IL 60607, USA.
Paul R Stabach
Ivana Simonović
Jon S Morrow
Miljan Simonović
University of Illinois Chicago · USYale University · US

Funding

MEMBRANE SKELETAL CONTROL IN HEMOLYTIC DISORDERSR01HL028560 · NHLBI · YALE UNIVERSITY · PI MORROW, JON S · 1985 to 2011
$3.3M
Topographic Spectrin Assembly in the Renal Tubule CellR01DK043812 · NIDDK · YALE UNIVERSITY · PI MORROW, JON S · 1991 to 2007
$1.9M
NHLBI NIH HHS R01 HL028560NHLBI NIH HHS R01-HL28560NIDDK NIH HHS R01 DK043812
6 · The paper itself

Abstract

The spectrin-based cytoskeleton is critical for cell stability, membrane organization and membrane protein trafficking. At its core is the high-affinity complex between beta-spectrin and ankyrin. Defects in either of these proteins may cause hemolytic disease, developmental disorders, neurologic disease, and cancer. Crystal structures of the minimal recognition motifs of ankyrin and beta-spectrin have been determined and distinct recognition mechanisms proposed. One focused on the complementary surface charges of the minimal recognition motifs, whereas the other identified an unusual kink between beta-spectrin repeats and suggested a conformation-sensitive binding surface. Using isothermal titration calorimetry and site-directed mutagenesis, we demonstrate the primacy of the inter-repeat kink as the critical determinant underlying spectrin's ankyrin affinity. The clinical implications of this are discussed in light of recognized linker mutations and polymorphisms in the beta-spectrins.

Indexed as

AnkyrinsMutationProtein ConformationRepetitive Sequences, Nucleic AcidSpectrinAnkyrinsSpectrin

Identifiers

PMID20079712
PMCPMC2839365
OpenAlexW2023425675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.